The MS therapy with anti-CD20 antibodies (Ocrelizumab – Ocrevus®, Ofatumumab – Kesimpta®, Ublituximab – Briumvi® and off-lable Rituximab) usually proceeds smoothly and without side effects, especially in younger patients – the drugs are all quite
Continue reading
For some time now, the patent protection for the multiple sclerosis (MS) drug Gilenya® (Fingolimod) has expired – the active ingredient Fingolimod can therefore now be marketed as a generic drug.
Continue reading
At the end of June, the European Medicines Agency (short: EMA) approved the Bruton’s tyrosine kinase inhibitor Tolebrutinib (amsel.de reported immediately). The BTKi is approved for the indication of secondary progressive multiple sclerosis without relapses
Continue reading
Another important study presented at this year’s AAN 2026 is the METEROID study. This is about the effect of Satralizumab in patients with MOGAD. MOGAD stands for Myelin Oligodendrocyte Glycoprotein Antibody Associated Disease. This is
Continue reading
At the end of April, the annual meeting of the American Academy of Neurology (AAN) took place in Chicago. I had the opportunity to attend the congress on site and therefore want to summarize some
Continue reading
Currently, social networks are probably being flooded with half-truths about lithium. – That’s the only way I can explain why I’ve been asked again and again recently by relatives of patients with Alzheimer’s disease about
Continue reading
Ublituximab in children, Vidofludimus Calcium in progression, Glatirameracetat in PPMS? All three were a topic at the ACTRIMS Congress in February 2026. Prof. Mathias Mäurer talks about the three active substances in this video. And
Continue reading
BTKi are considered to be the beacon of hope in the MS community, as they are supposed to specifically target and slow down the creeping parts of MS. BTKi are very small molecules that go
Continue reading
Tolebrutinib belongs to the class of Bruton tyrosine kinase inhibitors. Recently, negative news weakened hope for the BTKi, particularly among people with progressive multiple sclerosis. Professor Mathias Mäurer summarizes new information on Tolebrutinib in the
Continue reading
First of all, I would like to wish all readers of MS-DocBlog a happy and successful new year. – Stay healthy and hopeful, despite all adversities. Speaking of adversities – this brings us right back
Continue reading
Unsere Website verwendet Cookies und sammelt dabei Informationen über Ihren Besuch, um unsere Website zu verbessern (durch Analyse), Ihnen Social Media-Inhalte und relevante Werbung anzuzeigen. Weitere Informationen finden Sie auf unserer Seite . Sie können zustimmen, indem Sie auf die Schaltfläche "Akzeptieren" klicken.
Cookie-Einstellungen
Unten können Sie auswählen, welche Art von Cookies Sie auf dieser Website zulassen. Klicken Sie auf die Schaltfläche "Cookie-Einstellungen speichern", um Ihre Auswahl zu übernehmen.
Dieser Inhalt ist gesperrt. Akzeptieren Sie Cookies in der Kategorie '%CC%', um diesen Inhalt anzuzeigen.
